Zusammenfassung
Die Diagnose des Morbus Parkinson erfolgt nach klinischen Kriterien. In differenzialdiagnostisch schwierigen Fällen können die kranielle Kernspintomografie und nuklearmedizinische Untersuchungen wichtige Zusatzinformationen liefern, mit denen die Abgrenzung des Morbus Parkinson gegenüber atypischen und sekundären Parkinsonsyndromen unterstützt werden kann. Da zum Zeitpunkt der klinischen Diagnosestellung bereits eine weitgehende Degeneration nigraler Neuronen vorliegt, wird in Zukunft der Frühdiagnostik des Morbus Parkinson eine bedeutende Rolle zukommen. Hier werden verschiedene Verfahren wie der Riechtest, die Farbdiskrimination, die motorische Leistungsserie und der transkranielle Ultraschall diskutiert, wobei deren Sensitivität und Spezifität derzeit unklar ist.
Summary
Idiopathic ParkinsonŽs disease (PD) is diagnosed following clinical criteria. Cranial nuclear magnetic resonance imaging and nuclear medicine studies may help in cases with a difficult differential diagnosis of PD versus atypical and secondary parkinsonian syndromes. The earlier diagnosis of PD will become increasingly important since nigral degeneration has proceeded substantially at the time of clinical diagnosis. Different tools such as olfactory testing, color discrimination, motor performance test battery and transcranial ultrasound might allow an earlier diagnosis of PD, but sensitivity and specificity of these methods are not clear yet.
Key Words
Parkinson's disease - atypical parkinsonian syndromes - nuclear medicine diagnostics - nuclear magnetic resonance imaging
Literatur
-
1
Becker G, Seufert J. et al. .
Degeneration of substantia nigra in chronic ParkinsonŽs disease visualized by transcranial color-coded real-time sonography.
Neurology.
1995;
45
182-184
-
2
Benamer TS, Patterson J. et al. .
Accurate differentiation of parkinsonian and essential tremor using visual assessment of [123I]-FP-CIT-SPECT imaging: the [123I]-FP-CIT study group.
Mov Disord.
2000;
15
503-510
-
3
Berg D, Becker G. et al. .
Vulnerability of the nigrostriatal system as detected by transcranial ultrasound.
Neurology.
1999;
53
1026-1031
-
4
Bernheimer H, Birkmayer W. et al. .
Brain dopamine and the syndromes of Parkinson and Huntington.
J Neurol Sci.
1973;
20
415-455
-
5
Braune S.
The role of cardiac metaiodobenzylguanidine in the differential diagnosis of parkinsonian syndromes.
Clin Auton Res.
2001;
11
351-355
-
6
Büttner T, Kuhn W. et al. .
Distorted color discrimination in „de novo” parkinsonian patients.
Neurology.
1995;
45
386-387
-
7
Hughes AJ, Daniel SE. et al. .
Accuracy of clinical diagnosis of idiopathic ParkinsonŽs disease: a clinico-pathological study of 100 cases.
J Neurol Neurosurg Psychiatry.
1992;
55
181-184
-
8
Jellinger K.
New developments in the pathology of ParkinsonŽs disease.
In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH (Hrsg.) Advances in Neurology, Volume 53. ParkinsonŽs disease. Anatomy, pathology and therapy.
New York, Raven Press.
1990;
1-16
-
9
Kim YJ, Ichise. et al. .
Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP.
Mov Disord.
2002;
17
303-312
-
10
Kraus PH, Przuntek H. et al. .
Motor performance: normative data, age dependence and handedness.
J Neural Transm.
2000;
107
73-85
-
11
Pirker W, Asenbaum S. et al. .
[123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration.
Mov Disord.
2000;
15
1158-1167
-
12
Sage JL, Miller DC. et al. .
Clinically atypical expression of pathologically typical Lewy body parkinsonism.
Clin Neuropharmacol.
1990;
13
36-47
-
13
Tissingh G, Berendse HW. et al. .
Loss of olfaction in de novo and treated ParkinsonŽs disease: possible implications for early diagnosis.
Mov Disord.
2001;
16
41-46
-
14
Yoshita M.
Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy.
J Neurol Sci.
1998;
155
60-67
Korrespondenzadresse:
Dr. med. Jörg Spiegel
Neurologische Klinik, Universitätskliniken des Saarlandes
66421 Homburg/Saar
Email: nejspi@uniklinik-saarland.de
